AIkido Pharma (NASDAQ:AIKI) Upgraded to “Hold” by Zacks Investment Research

Zacks Investment Research upgraded shares of AIkido Pharma (NASDAQ:AIKIGet Rating) from a sell rating to a hold rating in a report published on Tuesday, Zacks.com reports.

According to Zacks, “AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The company’s pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. AIkido Pharma Inc., formerly known as Spherix Incorporated, is based in New York. “

AIkido Pharma stock opened at $0.36 on Tuesday. AIkido Pharma has a fifty-two week low of $0.30 and a fifty-two week high of $1.21. The stock has a market cap of $31.73 million, a PE ratio of -8.88 and a beta of 1.55. The firm’s 50-day simple moving average is $0.40 and its 200 day simple moving average is $0.47.

A number of institutional investors have recently added to or reduced their stakes in AIKI. Equitec Proprietary Markets LLC purchased a new position in AIkido Pharma during the first quarter worth about $134,000. Renaissance Technologies LLC purchased a new position in AIkido Pharma during the fourth quarter worth about $132,000. Citadel Advisors LLC purchased a new position in AIkido Pharma during the fourth quarter worth about $46,000. Finally, Geode Capital Management LLC boosted its holdings in AIkido Pharma by 5.3% during the third quarter. Geode Capital Management LLC now owns 732,780 shares of the business services provider’s stock worth $603,000 after purchasing an additional 36,724 shares during the last quarter. Institutional investors and hedge funds own 8.49% of the company’s stock.

About AIkido Pharma (Get Rating)

AIkido Pharma Inc, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.

Further Reading

Get a free copy of the Zacks research report on AIkido Pharma (AIKI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AIkido Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIkido Pharma and related companies with MarketBeat.com's FREE daily email newsletter.